Consensus revenue is $1.15 billion and EPS is $1.36 for Q3 2026, while Illumina's current price of $279.35 reflects significant recent momentum that places it above the average analyst target of $248.90.
Investors are primarily focused on Core Illumina organic revenue growth excluding China, which management previously guided to decelerate to approximately 4.5% this quarter.
The market is watching to see if the continued rollout of the NovaSeq X platform can sustain high clinical demand and drive consumable pull-through to offset cautious spending in the research and applied segments. Analysts are also closely monitoring operating margins, guided at 24%, as a key indicator of the company's efficiency following the strategic divestiture of GRAIL.